1. Introduction
===============

Cyclosporine is a calcineurin inhibitor used to prevent allograft rejection after transplantation, including solid organ transplantation and stem cell transplantation. Since it is characterized by a narrow therapeutic index and drug interactions occur frequently, its pharmacokinetic characteristics vary greatly among individuals, and daily doses must be adjusted to the whole-blood cyclosporine concentration.^\[[@R1]\]^ It is well clinically recognized that cyclosporine response shows significant interindividual variation among transplant patient.^\[[@R2]\]^ Exposure to cyclosporine is known to be closely associated with the acute rejection rate. Clase et al suggested that early adequate exposure to immunosuppressive agents is critical and that failing to reach target concentrations as early as the third postoperative day may result in acute rejection.^\[[@R3]\]^ Researching on the interindividual variability of cyclosporine pharmacokinetics is of critical importance for adjusting dosage to avoid rejection.

Cyclosporine is a substrate of P-glycoprotein (P-gp) and the product of the multidrug resistance gene (*MDR1*, also known as *ABCB1*).^\[[@R4]\]^ P-gp is a transmembrane efflux pump involving energy-dependent export of xenobiotics from inside to outside the plasma membrane.^\[[@R5]\]^ It may affect the absorption, distribution, and excretion of drugs in the body. *MDR1* encodes P-gp and its gene is highly polymorphic. So far, at least 32 single nucleotide polymorphisms (SNP) have been identified.^\[[@R6]\]^ Two synonymous SNPs (C1236T in exon 12 and C3435T in exon 26) and a non-synonymous SNP (G2677T in exon 21) have been found.^\[[@R2]\]^

Since the initial observation by Anglicheau et al indicated the effect of *MDR1* SNP C1236T expression, many studies have been performed on the influence of SNP C1236T on drug metabolism. However, the results were controversial. Haufroid et al^\[[@R4]\]^ reported no association was found between blood concentrations or dose and *MDR1* genotype. Qiu et al demonstrated it had a correlation between *MDR1* C1236T and cyclosporine pharmacokinetics in the early stage after transplantation.^\[[@R7]\]^ Fredericks et al suggested *MDR1* C1236T did not appear to have a major influence on cyclosporin pharmacokinetics.^\[[@R8]\]^

Moreover, there is no evidence from systematically evaluating the effect of *MDR1* C1236T on cyclosporine pharmacokinetics. It remains unclear about the reason for these conflicting results. The limited sample size of each single study could be another reason. Hence, this study conducts a meta-analysis to investigate whether SNP C1236T influences the pharmacokinetics of cyclosporine in transplant patients.

2. Materials and methods
========================

2.1. Literature search
----------------------

We designed a search strategy via 3 English language databases including PubMed, Embase and Cochrane Library. Four Chinese electronic database including China National Knowledge Infrastructure (CNKI), Wan Fang Database (Wan Fang), Chinese Biomedical Literature Database (CBM), and VIP Database for Chinese Technical Periodicals (VIP) were also searched in Chinese.

The following principal search terms and MeSH headings were used: "cyclosporine" or "ciclosporin" or "CsA" and "polymorphism" or "genotype" or "genes" or "alleles" or "SNP" and "*MDR1*" or "MDR-1" or "ABCB1." We would look for additional studies in reference lists of included articles, contact with authors about details of published or unpublished articles. The results were crosschecked to eliminate duplicates. The deadline of all retrieval was December 2016.

2.2. Study selection
--------------------

The following studies were included in analysis: patients treated with cyclosporine, regardless of race, sex; patients needed to accept *MDR1 Cl236T* gene polymorphism detection and detection methods are not limited; and studies published in either English or Chinese. Studies with incomplete information were excluded from the analysis.

2.3. Data extraction
--------------------

Data extraction form designed according to Cochrane Systematic Review Handbook (version 5.3) was used to extract the relevant information independently. Two independent reviewers screened all the titles and abstracts to determine potential usefulness and eligibility of the articles. Then they independently and blindly applied the eligibility criteria to perform the final selection. When discrepancies occurred between both reviewers regarding the inclusion of the articles, they would discuss and identify the reasons of inclusion or exclusion to make an agreement and take a final decision. If they could not reach agreement, a final decision would be based on a third reviewer.

2.4. Statistical analysis
-------------------------

Meta-analysis was conducted with RevMan 5.3. The data was pooled and as analyzed for relative risks (RR) with 95% confidence interval (CI). Assessment of heterogeneity was done by *I*-squared (*I*^2^) statistics. A fixed-effects model was initially conducted. If significant heterogeneity was found among trials (*I*^2^ \> 50%), a random-effects model was used.

2.5. Ethical statement
----------------------

As all analyses were grounded on previous publications, ethical approval was not necessary.

3. Results
==========

3.1. Study selection and characteristics
----------------------------------------

A total of 608 records were identified for initial screening and 11 eligible articles were included in this meta-analysis (Fig. [1](#F1){ref-type="fig"}). These studies were published between 2004 and 2013. Of these 11 articles, patients from 7 articles were treated with renal transplantation, 3 were treated with bone marrow transplant, and 1 was treated with myasthenia gravis. The meta-analysis results were presented in Table [1](#T1){ref-type="table"}.
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Characteristics of included studies.
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3.2. Effect of C1236T on dose adjusted C~0~
-------------------------------------------

A total of 8 studies in Table [1](#T1){ref-type="table"} assessed the relationship between SNP C1236T and dose adjusted C~0~. There was no significant difference between subjects carrying CC genotypes and CT genotypes (MD: 0.24, 95% CI \[−4.39, 4.86\], *P* = .92) with no heterogeneity. The Q-statistic indicated significant heterogeneity between subjects carrying CC genotypes and TT genotypes, as well as between subjects carrying CT genotypes and TT genotypes. After sensitivity analysis (excluding the study of Zhang 2008 and Wang 2009, respectively), there was significant difference between subjects carrying CC genotypes and TT genotypes (MD: 6.76, 95% CI \[2.38, 11.14\], *P* = .02\]. However, there was no significant difference between subjects carrying CT genotypes and TT genotypes (MD: 3.12, 95% CI \[−0.59, 6.82\], *P* = .1) with no significant heterogeneity (Fig. [2](#F2){ref-type="fig"}).
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3.3. Effect of C1236T on dose adjusted C~2~
-------------------------------------------

A total of 3 studies in Table [1](#T1){ref-type="table"} reported the relationship between SNP C1236T and dose adjusted C~2~. There was difference between subjects with CC genotypes and CT genotypes (MD: −18.50, 95% CI \[−35.49, −1.52\], *P* = .03) with no significant heterogeneity, as well as between subjects with CC genotypes and TT genotypes (MD: −19.01, 95% CI \[−35.85, −2.16\], *P* = .03\]. However, there was no difference between subjects carrying CT genotypes and TT genotypes (MD: −7.02, 95% CI \[−17.11, 3.07\], *P* = .17\] with no heterogeneity (Fig. [3](#F3){ref-type="fig"}).
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3.4. Effect of C1236T on dose adjusted C~max~
---------------------------------------------

A total of 3 studies in Table [1](#T1){ref-type="table"} reported the relationship between SNP C1236T and dose adjusted C~max~. There was no difference between subjects carrying CC genotypes and CT genotypes (MD: −0.05, 95% CI \[−0.10, 0.01\], *P* = .12), CC genotypes and TT genotypes (MD: −0.05, 95% CI \[−0.11, 0.01\], *P* = .08), as well as CT genotypes and TT genotypes (MD: 0.01, 95% CI \[−0.04, 0.09\], *P* = .79). At the same time, the 3 subgroups had no heterogeneity (Fig. [4](#F4){ref-type="fig"}).
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3.5. Effect of C1236T on daily dose
-----------------------------------

A total of 6 studies in Table [1](#T1){ref-type="table"} reported the relationship between C1236T SNP and daily dose. Q-statistic indicated significant heterogeneity between subjects carrying CC genotypes and CT genotypes. After sensitivity analysis (excluding the study of Zhang 2008), there was no difference between subjects carrying CC genotypes and CT genotypes (MD: 0.08, 95% CI \[−0.18, 0.33\], *P* = .57). Moreover, there was no difference between subjects carrying CC genotypes and TT genotypes (MD: 0.10, 95% CI \[−0.13, 0.33\], *P* = .40), as well as CT genotypes and TT genotypes (MD: 0.17, 95% CI \[−0.01, 0.35\], *P* = .07) (Fig. [5](#F5){ref-type="fig"}).
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3.6. Effect of C1236T on C~0~
-----------------------------

A total of 6 studies in Table [1](#T1){ref-type="table"} reported the relationship between C1236T SNP and C~0~. There was no difference between subjects carrying CC genotypes and CT genotypes (MD: 4.75, 95% CI \[−7.67, 17.18\], *P* = .45), CC genotypes and TT genotypes (MD: 4.84, 95% CI \[−7.98, 17.66\], *P* = .46), as well as CT genotypes and TT genotypes (MD: −1.39, 95% CI \[−9.76, 7.00\], *P* = .75). At the same time, the 3 subgroups had no heterogeneity (Fig. [6](#F6){ref-type="fig"}).
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4. Discussion
=============

The characterization of *MDR1* gene and the utilization of pharmacogenetic testing for the identification of different *MDR1* alleles may provide a useful tool for optimizing therapy involved with drugs that are substrates of P-glycoprotein, which would improve efficacy of drugs and prevent adverse effects.^\[[@R17]\]^ Since the studies on the correlation between genotype of *MDR1* C1236T and pharmacokinetics of cyclosporine revealed conflicting results, this meta-analysis mainly assessed the effect of SNP C1236T on pharmacokinetic parameters of cyclosporine.

Pharmacokinetic studies on transplant patients have demonstrated that the area under the concentration time curve (AUC) is a precise predictor of clinical outcomes.^\[[@R18]\]^ However, the AUC methodology is difficult to apply in routine clinical practice, so other methods have been developed to replace the AUC, such as C~0~, C~2~.^\[[@R19]\]^ This explains the reason why AUC is rarely reported in the included studies.

Trough concentration (C~0~) and dose adjusted C~0~ are the most common parameters in included studies. It is interesting to find there was no significant difference in C~0~. But a significant difference was showed in dose adjusted C~0~ in included studies. This suggested that we could choose dose adjusted C~0~ of pharmacokinetic parameters as a detection indicator, to further guide the rational use of cyclosporine dose in different genotype of *MDR1* C1236T patients. Through subgroup analysis of dose adjusted C~0~, the results suggested there was difference between subjects carrying CC genotypes and TT genotypes.

Whole-blood levels at 2 hours after drug intake (C~2~) seem to provide a good surrogate of AUC for dose adjustment, which may better reflect intestinal absorption because it decreases the role of hepatic metabolism and renal excretion.^\[[@R20]\]^ Through subgroup analysis of adjusted C~2~, the results suggested there was significant difference between subjects carrying CC genotypes and CT genotypes, as well as CC genotypes and TT genotypes. However, this meta-analysis shows SNP C1236T has no significant difference in C~max~ and daily dose, which might demonstrate that the effect of different C1236T genotypes on the availability of cyclosporine was limited.

Although this meta-analysis analyzed the correlation between pharmacokinetic parameters and genotypes of *MDR1* C1236T, we recognized that our study still has limitations. First, since these studies are different in design, subjects, dosage, parameters, measurement method, and so on, selection bias exists in this meta-analysis. Second, C1236T is one of the *MDR1* SNPs, meaning that it is not the only polymorphism that could influence the *MDR1* expression. Third, this meta-analysis did not find a definitive correlation between pharmacokinetic parameters and genotype of *MDR1* C1236T. Balram et al indicated race maybe one important factor affecting the pharmacokinetic parameters of cyclosporine.^\[[@R21]\]^ Chowbay et al suggested that *MDR1* haplotype, rather than single SNP polymorphism, might be responsible for influencing P-glycoprotein expression, thus influencing the pharmacokinetic parameters of cyclosporine.^\[[@R22]\]^ Cyclosporine is also the substrate of CYP3A4 and CYP3A5 and polymorphism of CYP3A has the potential to affect cyclosporine metabolism.^\[[@R23]\]^ Therefore, many facts would affect the correlation between pharmacokinetic parameters and genotypes of *MDR1* C1236T. It is hard to find a definitive correlation and we should be cautious with our results.

In summary, this meta-analysis demonstrated that MDR1 C1236T polymorphism may have a minor effect on cyclosporine pharmacokinetics in transplantation patients.
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